BIIB Q1 2023 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q1 2023 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.5B-2.7% YoY

Gross Profit

$1.8B73.1% margin

Operating Income

$574M23.3% margin

Net Income

$388M15.7% margin

EPS (Diluted)

$2.67

QoQ Revenue Growth

-3.2%

Cash Flow

Operating Cash Flow

$455M

Free Cash Flow

$389M

Stock-Based Comp.

$76M

Balance Sheet

Total Assets

$24.6B

Total Liabilities

$10.8B

Stockholders' Equity

$13.8B

Cash & Equivalents

$2.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.5B	$2.5B	-2.7%
Gross Profit	$1.8B	$1.8B	+1.3%
Operating Income	$574M	$524M	+9.5%
Net Income	$388M	$304M	+27.7%

Revenue Segments

MS Product Revenues

$1.1B42%

TYSABRI product

$473M18%

SPINRAZA

$443M17%

Fumarate

$383M14%

Interferon

$246M9%

Geographic Segments

Non-US

$1.1B60%

UNITED STATES

$701M40%